Neal Shore, MD, FACS

PSMA PET improves staging in advanced and recurrent prostate cancer, guiding shared decisions with expert interpretation and paving the way for theranostics.

New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA.

Real-world PSMA PET use in prostate cancer reveals variable readings and PSA thresholds, prompting selective scans and ongoing trials with FDG PET.

Learn how evolving PSMA PET reporting standards reshape prostate cancer staging and influence therapy choices, from SBRT to triplet regimens.

Learn who reads PSMA PET scans and why a multidisciplinary team translates results into clearer prostate cancer treatment and imaging decisions.

Learn how next‑gen prostate cancer imaging outperforms CT and bone scans, revealing micrometastases and guiding team-based treatment decisions.